Breaking News

You are here » Indian-Commodity  :  Commodities  :  Turmeric  :  Turmeric futures trade lower on higher production prospects

22-Jan2019

Turmeric futures trade lower on higher production prospects

Turmeric futures traded lower on NCDEX, due to expectation of higher production prospects this season amid higher acreage in Telangana. However, good exports and improving domestic demand restricted some losses.

The contract for April delivery was trading at Rs 6588.00, down by 0.45% or Rs 30.00 from its previous closing of Rs 6618.00. The open interest of the contract stood at 13190 lots.

The contract for May delivery was trading at Rs 6630.00, down by 0.51% or Rs 34.00 from its previous closing of Rs 6664.00. The open interest of the contract stood at 530 lots on NCDEX.


Related News

View all news

Turmeric futures trade lower on improved crop prospects

Turmeric futures traded lower on NCDEX, due to trimming of bets by market players on the back of improved crop prospects in Maharashtra. Further, expectation of fresh arrivals at the spot market amid sufficient......

Turmeric futures trade mixed on NCDEX

Turmeric futures traded mixed on NCDEX, as contract for April traded up on the back of concerns that drought conditions and cold weather will affect the crop production, while contract for May traded down......

Turmeric futures trade lower on NCDEX

Turmeric futures traded lower on NCDEX, on the back of improved crop prospects in Maharashtra. Further, expectation of higher production this season due to higher acreage in Telangana also fuelled the......

Top News

View all news

Tata Motors signs LTS agreement with its employees

Tata Motors has signed a long-term wage settlement (LTS) agreement with its employees. Under the agreement, workmen will get a wage rise of Rs 9,000 per month along with other incentives based on performance.......

Canara Bank invites bids from merchant bankers to manage its $350-500 million MTN issue: Report

Canara Bank has reportedly invited bids from merchant bankers to manage its $350-500 million issue of senior unsecured/tier-II capital bonds under its medium-term note (MTN) programme. The issue size may......

Alembic Pharma gets USFDA's nod for Acetazolamide Extended-Release Capsules

Alembic Pharmaceuticals (Alembic) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acetazolamide Extended-Release Capsules, 500......